drug_type
RELEVANT_DRUG
intervention_type
Biological (autologous gene-modified T-cell therapy)
drug_description
Autologous gene-modified T-cell therapy: patient T cells are collected, transduced ex vivo with a lentiviral vector encoding the EB103 transgene, then reinfused to redirect and activate T cells against malignant B-cell non-Hodgkin lymphoma (CAR-like signaling) leading to antigen-specific proliferation and cytotoxic killing.
nci_thesaurus_concept_id
C209361
nci_thesaurus_preferred_term
Autologous Anti-CD19 AbTCR-expressing T-lymphocytes EB103
nci_thesaurus_definition
A preparation of autologous T-lymphocytes transduced with a lentiviral vector encoding an antibody-T-cell-receptor (AbTCR) composed of a CD19-binding domain derived from an antibody fragment antigen binding (Fab) region and an effector domain derived from human gamma/delta TCR, and a co-stimulatory molecule composed of a CD19-binding domain derived from a single-chain variable fragment (scFv) and a co-stimulatory domain derived from a human co-stimulatory receptor, with potential immunostimulating and antineoplastic activities. Upon administration of the autologous anti-CD19 AbTCR-expressing T-lymphocytes EB103, both the AbTCR moiety and the co-stimulatory molecule recognize and bind to CD-19-expressing tumor cells, resulting in specific T-cell-mediated tumor cell lysis. CD19, a B-cell-specific cell surface antigen, is overexpressed in B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are transduced ex vivo with a lentiviral vector to express an anti‑CD19 antibody‑TCR (AbTCR) and a costimulatory molecule, enabling MHC‑independent recognition of CD19 on B‑cell malignancies. Upon reinfusion, engagement of CD19 triggers CAR‑like activation, proliferation, and T‑cell–mediated cytotoxic killing of tumor cells.
drug_name
EB103
nct_id_drug_ref
NCT06343311